back to US directory
us clinical guidance

Adult non-cystic-fibrosis bronchiectasis

The 2026 CHEST approach to exacerbation antibiotics, airway clearance, suppressive treatment, hemoptysis and selected surgery.

JurisdictionUnited States
Source check2026-08-20
Clinical reviewiatroX editorial team 路 Clinical editorial review 路 reviewed 2026-08-20 路 due 2027-08-20
AudienceUnited States healthcare professionals
This is an iatroX educational summary of named United States sources, not an official guideline. It does not replace the complete source documents, local policy, specialist advice or clinical judgement. Use the named authority, current FDA labeling, applicable state law, payer rules and local protocol where relevant.

Scope of this summary

Adults with established bronchiectasis not caused by cystic fibrosis. The 2026 CHEST guideline addresses eight treatment questions and makes 13 conditional recommendations, mostly from low-certainty evidence; it is not a complete diagnostic, etiologic-testing or transplant guideline and does not apply automatically to children.
sources for this section:CHEST bronchiectasis 2026

The Bottom Line

  • Use airway-clearance techniques as a central component of care and individualize the method with trained respiratory or physical-therapy support, patient preference and response.
  • For an acute exacerbation, select antibiotic treatment using current or prior airway microbiology and the clinical context whenever possible rather than applying one regimen to every patient.
  • Individualize antibiotic route and duration to severity, organism, prior resistance, response and treatment burden; collect sputum before treatment when feasible without delaying care in a seriously ill patient.
  • For frequent exacerbations, discuss long-term suppressive or anti-inflammatory options only after phenotype, microbiology, airway clearance, adherence, adverse effects, cost and patient priorities are reviewed.
  • Frame every 2026 recommendation as conditional and use shared decision-making because certainty is generally low and treatment burden can be substantial.
sources for this section:CHEST bronchiectasis 2026

Practical clinical workflow

1
Confirm that the clinical and CT diagnosis is established and document symptoms, exacerbation frequency, lung function, sputum microbiology, hemoptysis, prior treatment and plausible underlying cause.
2
Arrange a personalized airway-clearance program, physical activity and appropriate pulmonary rehabilitation; reassess whether the technique is practical and effective.
3
At deterioration, obtain sputum microbiology when possible, compare prior isolates and susceptibilities, grade severity, consider alternative diagnoses and begin targeted treatment without unsafe delay.
4
Before chronic macrolide, inhaled antibiotic or another suppressive strategy, review the guideline indication plus antimicrobial resistance, nontuberculous mycobacteria, hearing, cardiac rhythm, interactions and treatment burden as applicable.
5
Use multidisciplinary review for persistent exacerbations, difficult organisms, significant hemoptysis, progressive respiratory impairment or localized disease being considered for resection.
sources for this section:CHEST bronchiectasis 2026

Safety boundaries and escalation

  • Major or recurrent hemoptysis, acute respiratory failure, hemodynamic instability or severe sepsis requires emergency assessment and coordinated pulmonary, critical-care and interventional expertise.
  • Do not extrapolate cystic-fibrosis regimens or routine inhaled-corticosteroid treatment to non-CF bronchiectasis without another indication and source-specific support.
  • Check for nontuberculous mycobacterial disease before long-term macrolide monotherapy where applicable, and monitor resistance, toxicity and interactions during any suppressive regimen.
  • Surgical resection is reserved for carefully selected localized, refractory disease after multidisciplinary assessment; this page does not define operative candidacy.
sources for this section:CHEST bronchiectasis 2026

Localization

This page uses the new 2026 American College of Chest Physicians guideline and intentionally avoids copying its recommendations table. US culture access, FDA labeling, insurance coverage and specialty infrastructure affect choices.
sources for this section:CHEST bronchiectasis 2026

Source documents

Use the linked source documents for complete recommendations, evidence grading, exclusions and implementation detail.

  1. American College of Chest PhysiciansManagement of Adult Bronchiectasis: An American College of Chest Physicians Clinical Practice GuidelineDOI 10.1016/j.chest.2026.06.057 路 published 2026-07-21 路 accessed 2026-08-20
    view source
continue the learning

From guidance to deliberate practice and evidence

Choose what happens next. iatroX can carry this page's jurisdiction, source-check date and released version into an editable learning record, support your reflection, or let you browse the regional question bank while keeping this topic visible. No action records completion, starts a session or awards CPD/CME credit automatically.

Add this guidance review to CPD/CMEOpen an editable learning-log record with this page鈥檚 provenance attached. You confirm the activity, time, reflection and mappings.Reflect on this with TutorUse optional prompts to consider what you learned and what鈥攊f anything鈥攜ou may change. Suggestions are never inserted automatically.Browse the US question bankKeep this guidance topic in view, then choose your exam and filters. No session starts automatically.
Found a source update or regional discrepancy? Tell the iatroX editorial team.